• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks
    life science investing

    Prostate Surgery Best First-Line Treatment for Localized Prostate Cancer, Study Says

    Vivien Diniz
    Mar. 05, 2014 11:53AM PST
    Life Science Investing News

    A major European study, recently found that men with localized prostate cancer who choose prostate removal surgery have a higher rate of survival than those who opt for radiotherapy

    A major European study, recently found that men with localized prostate cancer who choose prostate removal surgery have a higher rate of survival than those who opt for radiotherapy. The 15-year study catologed more than 34,000 Swedish men who underwent the treatment.

    According to the company’s press release:

    While the highest survival rates were seen among younger patients with non-metastatic prostate cancer, even older men within the more advanced stages of the disease benefited from the surgery-first approach. David B. Samadi, MD, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital, world-renowned prostate cancer expert and inventor of the Samadi Modified Advanced Robotic Technique (SMART) for prostate surgery, emphasized that the study results are consistent with his long held views on the benefits of prostate surgery. “When prostate cancer is diagnosed early, robotic surgery is the best way to optimize prostate cancer recovery and long-term survival.”

    Click here to view the full press release. 

     

    prostate cancerlife science investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    XTANDI®  plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

    XTANDI® plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing News Stocks

    Defence Therapeutics Class A

    DTC:CC

    Cloud DX

    CDX:CA

    BioHarvest Sciences

    BHSC:CNX

    Billy Goat Brands

    GOAT:CC

    Contakt World

    HELP:CNX
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×